DNA Microarray 2013: A Focus on Sales Growth

NEW YORK, Aug. 13, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

DNA Microarray 2013: A Focus on Sales Growth
http://www.reportlinker.com/p0980749/DNA-Microarray-2013-A-Focus-on-Sales-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

Summary: This market analysis was carried out to provide business information to developers, manufacturers and suppliers in the DNA microarray field. Its findings include:

- Marketing and sales opportunities
- End-user purchasing decisions
- Market growth and shrinkage
- Innovation and new product opportunities
This study was conducted through specialist groups of experienced DNA microarray end-users and its findings are therefore based on 'real world' market data.

Market Analysis and Opportunities

A competitive market analysis of current practices and future developments across 25 key market areas in the DNA microarray field. Examples include:
- DNA Microarray Techniques: Which DNA microarray techniques are the market leaders and what changes do end-users predict over the next three years. Which DNA microarray techniques are growing and which are reducing?
- DNA Microarray Applications: Which DNA microarray applications are the market leaders and what changes do end-users predict over the next three years. Which DNA microarray applications are growing and which are reducing?
- Suppliers: Who are the major company suppliers in the DNA microarray field and who do flow cytometry end-users plan to purchase from over the next three years. Who are the top ten suppliers in this field, and what changes are predicted in three years from now.
- Opportunities: The findings of this study are analysed to identify opportunities to suppliers in the DNA microarray field, in the 'Market Areas' indicated below.

Overview

This market study was carried out to assist developers, manufacturers and suppliers in the DNA microarray field, in marketing and sales. It was conducted through specialist groups of experienced clinical and laboratory microarray end-users, and its findings are based on 'real word' market data. By working closely with experienced microarray end-users, we were able to identify current and emerging commercial opportunities in this growing market.
From the early use of miniaturised microarrays for gene expression analysis in the mid 1990s, this technique has established markets that are expected to reach $3 billion by 2015. DNA Microarray 2013 presents the findings of a global market study of DNA Microarray, involving the participation 201 experienced microarray end-users. With a focus on market development, sales growth and commercial opportunities, this study profiled current and evolving areas of this market, as outlined below.

Market Areas

- Current use of microarray: Use of antibody microarray by end-users for running routine (developed and validated) microarray tests, the development or validation of microarray tests and for the qualitative discovery using microarray methods.
- Participants: Name, organisation, department, job title, and country
- Organisation type: Clinics/hospitals, Government bodies, large international companies, research institutes, small and medium sized companies, universities and veterinary centres.
- Fields: Biotechnology, chemicals, clinical or hospital, defence, energy, environmental, food and drink, forensics, geology, government, healthcare, natural products, pharmaceuticals, research institutes, security and universities.
- Purpose: Purposes or reasons for using microarray across 16 major fields previously indicated. As the purposes or reasons differ with field, each was considered individually and presented to appropriate study participants. As an example, the potential reasons for using microarray in clinics and hospitals were clinical research, routine diagnostics, routine screening, clinical trials, treatment monitoring, diagnostics research, disease research, drug R&D, drug targets, pathology, toxicology or other [please contact Biopharm Reports if you require the full (16) industry-specific listings].
- Microarray techniques: The main microarray technique used in the laboratory or clinic, where the options were antibody microarray*, DNA microarray, protein microarray**, tissue microarray or other [* antibodies attached to microarrays as capture molecules, ** a variety of different proteins (other than antibodies) attached to microarrays as capture molecules (e.g. enzymes, receptors etc].
- Therapeutic areas: Use of antibody microarray, DNA microarray, protein microarray and tissue microarray in 22 therapeutic areas, namely, arthritis, autoimmune diseases, bone metabolism, cancer, cardiovascular, central nervous system, dermatology, endocrine, gastrointestinal, genito-urinary system, haematology, infections, inflammation, metabolic disorders, musculoskeletal disorders, nutrition, obstetrics, and gynaecology, ophthalmology, pain, respiratory, skin, other or not applicable.

- Study samples: Study sample types analysed by antibody microarray, DNA microarray, protein microarray and tissue microarray, namely animal tissues, cell isolates, cells, cerebrospinal fluid, genetic material, human tissues, In-vitro biological solutions, microbiological materials, pathology samples, plasma, saliva, serum, urine, whole blood or other.
- Sample Preparation: The use of sample preparation methods for antibody microarray, DNA microarray, protein microarray and tissue microarray studies, namely automated sample preparation, solid-Phase extraction (SPE), liquid-liquid extraction (LLE), size exclusion, organic solvent precipitation, direct injection, dialysis, affinity methods, Filtration and Other.
- Current microarray methods: Current use of antibody microarray methods, DNA microarray methods, protein microarray methods and tissue microarray methods, where the options are: direct labeling (of study molecules), dual-antibody sandwich methods or other for antibody microarray; chromatin immunoprecipitation on chip (ChlP Chip), comparative genomic hybridization Array, cpG island custom array, DamID array, DNA methylation array, exon junction array, gene array, gene copy number array, gene expression-profiling (cDNA) array, geneID array, miRNA array, proximity ligation array, SNP detection array, tiling array or other for DNA microarray; general protein-protein interactions, enzyme-substrate interactions, protein activations or deactivations, protein-cell interactions, protein-polynucleotide interactions, protein-small molecule interactions or other for protein microarray; and immunohistochemistry, fluorescence in-situ hybridisation (FISH) or other for tissue microarray.
- Future microarray methods: Anticipated use over the next three years of antibody microarray methods, DNA microarray methods, protein microarray methods and tissue microarray methods, where the options are: direct labeling (of study molecules), dual-antibody sandwich methods or other for antibody microarray; chromatin immunoprecipitation on chip (ChlP Chip), comparative genomic hybridization Array, cpG island custom array, DamID array, DNA methylation array, exon junction array, gene array, gene copy number array, gene expression-profiling (cDNA) array, geneID array, miRNA array, proximity ligation array, SNP detection array, tiling array or other for DNA microarray; general protein-protein interactions, enzyme-substrate interactions, protein activations or deactivations, protein-cell interactions, protein-polynucleotide interactions, protein-small molecule interactions or other for protein microarray; and immunohistochemistry, fluorescence in-situ hybridisation (FISH) or other for tissue microarray
- Current microarray applications: Current use of antibody microarray applications, DNA microarray applications, protein microarray applications and tissue microarray applications, where the options are: routine clinical diagnosis, clinical diagnostics R&D, disease biomarker discovery, drug R&D, forensic studies, general disease research, general proteomics, protein expression levels, multiplex immunoassays and other for antibody microarray; alternative splicing, comparative genomic hybridization (DNA Arrays), DamID (Protein Binding site Occupancy), fusion gene transcripts, protein binding site occupancy (by ChlP), DNA capture, DNA copy number, epigenetic analyses, for FISH assays, for PCR, gene expression, gene identification, geneID (e.g. pathogens), identify miRNA, mutation identification, SNP detection, whole genome analysis (DNA Array) or other for DNA microarray; proteomics, drug discovery, fundamental protein research, biomarker studies, cell signalling, disease research, clinical diagnostics, toxicology, protein expression and other for protein microarray; and routine clinical diagnosis, clinical diagnostics R&D, animal (non-human) tissue research, human tissue research, drug research, forensic studies, general disease research, post-mortem studies and other for tissue microarray.
- Future microarray applications: Anticipated use over the next three years of antibody microarray applications, DNA microarray applications, protein microarray applications and tissue microarray applications, where the options are: routine clinical diagnosis, clinical diagnostics R&D, disease biomarker discovery, drug R&D, forensic studies, general disease research, general proteomics, protein expression levels, multiplex immunoassays and other for antibody microarray; alternative splicing, comparative genomic hybridization (DNA Arrays), DamID (Protein Binding site Occupancy), fusion gene transcripts, protein binding site occupancy (by ChlP), DNA capture, DNA copy number, epigenetic analyses, for FISH assays, for PCR, gene expression, gene identification, geneID (e.g. pathogens), identify miRNA, mutation identification, SNP detection, whole genome analysis (DNA Array) or other for DNA microarray; proteomics, drug discovery, fundamental protein research, biomarker studies, cell signalling, disease research, clinical diagnostics, toxicology, protein expression and other for protein microarray; and routine clinical diagnosis, clinical diagnostics R&D, animal (non-human) tissue research, human tissue research, drug research, forensic studies, general disease research, post-mortem studies and other for tissue microarray.

- Current microarray company suppliers: Current use of microarray methods based on supplies from 13, 29, 14, and 16 companies, for antibody microarray, DNA microarray, protein microarray and tissue microarray, respectively.
- Future microarray company suppliers: Anticipated use over the next three years of methods based on supplies from 13, 29, 14, and 16 companies, for antibody microarray, DNA microarray, protein microarray and tissue microarray, respectively.
- Current capture molecules: [this question was directed at users of protein microarray only] Current use of specific capture proteins in protein microarray, where the options were enzymes, oligopeptides, antigens, cell surface proteins (e.g. receptors), intracellular proteins, free proteins (e.g. present in biological fluids), protein mimics or other.
- Future capture molecules: [this question was directed at users of protein microarray only] Anticipated use over the next three years of specific capture proteins in protein microarray, where the options were enzymes, oligopeptides, antigens, cell surface proteins (e.g. receptors), intracellular proteins, free proteins (e.g. present in biological fluids), protein mimics or other.
- Tissue types: [this question was directed at users of tissue microarray only] The top three tissue types used in tissue microarray methods.
- Current tissue microarrays: [this question was directed at users of tissue microarray only] Current use of tissue microarrays in terms of those prepared in-house or alternatively, those purchased ready to use.
- Future tissue microarrays: [this question was directed at users of tissue microarray only] Anticipated use over the next three years of tissue microarrays that are prepared in-house or alternatively, purchased ready to use.
- Preferred Companies: Preferred Company in the antibody microarray, DNA microarray, protein microarray and tissue microarray field.
- Preferred products: Preferred product from the preferred Company in the antibody microarray, DNA microarray, protein microarray and tissue microarray fields.
- Strengths: The strengths of the preferred product in the antibody microarray, DNA microarray, protein microarray and tissue microarray fields.

- Weaknesses: The weaknesses of the preferred product in the antibody microarray, DNA microarray, protein microarray and tissue microarray fields.
- Bioinformatics software: preferred bioinformatics software, used in antibody microarray, DNA microarray, protein microarray and tissue microarray studies.
- Disease biomarkers: The use (or not) of antibody microarray, DNA microarray, protein microarray and tissue microarray for the study of disease biomarkers (options yes or no).
- Disease biomarker groups: The use of antibody microarray, protein microarray and tissue microarray for the study of disease biomarkers, where the options are: Genetic molecules (e.g. DNA, mRNA, MicroRNA etc.), non-genetic molecules (e.g. proteins, metabolites)**, or other [**for the purpose of this survey, "non-genetic" molecules means ALL molecules, other than oligonucleotides or polynucleotides].
- Disease biomarker types: The use of antibody microarray, DNA microarray, protein microarray and tissue microarray for the study of disease biomarkers, where the options are: amino acids, glycoproteins, lipids, metabolites, proteins (cell surface), proteins (free form in biological fluids e.g. blood, urine etc), proteins (intracellular), short peptides, oligonucleotides, polynucleotides or other for antibody microarray; Gene variations (mutations/polymorphisms), DNA methylation, Gene copy number, Gene expression, SNPs, miRNA, alternative splicing variants or other for DNA microarray; amino acids, glycoproteins, lipids, metabolites, proteins (cell surface) proteins (free form in biological fluids e.g. blood, urine etc), proteins (intracellular), short peptides, Oligonucleotides, polynucleotides or other for protein microarray and tissue microarray.
- Disease biomarker utility: The use of disease biomarkers studied using antibody microarray, DNA microarray, protein microarray and tissue microarray in terms of their clinical utility, where the options are disease prognosis, disease susceptibility or risk, disease stage or severity, drug discovery, early detection of disease, clinical trial endpoint, guidance of treatment, response to therapy, safety or toxicity factors or other.
- Challenges: The molecular type or parameter that presents the greatest technical challenge (qualitatively or quantitatively) in antibody microarray, DNA microarray, protein microarray and tissue microarray, including molecule type, sample type and antibody microarray, DNA microarray, protein microarray and tissue microarray method used.
- Main reasons: The main reasons for the technical challenges relating to the measurement of the molecular type or parameter referred to previously, using the antibody microarray, DNA microarray, protein microarray and tissue microarray method indicated.
- Required innovation: The areas where innovation is most required (on a scale of 1-10) in antibody microarray, DNA microarray, protein microarray and tissue microarray, where the options are sample preparation, ancillary techniques, array (qualitative) selectivity, array (quantitative) sensitivity, array reproducibility, array qualitative/quantitative capability, array robustness (ruggedness), detection methods, automation, speed or sample throughput, specialist data control systems, specialist bioinformatics systems or other
- Recent innovations: The most important innovations in the use of antibody microarray, DNA microarray, protein microarray and tissue microarray fields over the last three years.
- Future innovation: The most important anticipated innovations in the antibody microarray, DNA microarray, protein microarray and tissue microarray fields, over the next three years.
- Ancillary procedures: The two most important ancillary procedures in the use of antibody microarray, DNA microarray, protein microarray and tissue microarray methods.
- Financial budgets: Annual financial budgets relating to the use of antibody microarray, DNA microarray, protein microarray and tissue microarray methods.
- Current Budget breakdown: The breakdown of current financial budgets relating to the use of antibody microarray, DNA microarray, protein microarray and tissue microarray methods in terms of consumables, system control software, specialist bioinformatics software, microarrays/instruments, sample preparation/related instrumentation, ancillary systems/instrumentation, general overheads, staff salaries and other
- Future budget breakdown: The anticipated breakdown of over the next three years of financial budgets relating to the use of antibody microarray, DNA microarray, protein microarray and tissue microarray methods, in terms of consumables, system control software, specialist bioinformatics software, microarrays/instruments, sample preparation/related instrumentation, ancillary systems/instrumentation, general overheads, staff salaries and other.
- Future overall budgets: Anticipated changes in overall financial budgets (percentage increases or decrease) over the next three years, relating to antibody microarray, DNA microarray, protein microarray and tissue microarray activities
- Consumables: Top three consumables in terms of costs, associated with antibody microarray, DNA microarray, protein microarray and tissue microarray activities
- Quality Control guidelines: Adherence to quality control guidelines or procedures, relating to the conduct of antibody microarray, DNA microarray, protein microarray and tissue microarray studies.

Executive Summary

Chapter 1 Introduction

Chapter 2 Study Participants

2.1 This Chapter
2.2 Countries
2.3 Regions
2.4 Organisation Types
2.5 Fields
2.6 Microarray Types
2.7 Participants
2.8 Discussion

Figure 2.1 Countries of individuals who participated in Microarray 2012
Figure 2.2 Global regions of individuals who participated in Microarray 2012.
Figure 2.3 Organisation types of individuals who participated in Microarray 2012
Figure 2.4 Fields of individuals who participated in Microarray 2012
Table 2.1 Countries of individuals who participated in Microarray 2012
Table 2.2 Global regions of individuals who participated in Microarray 2012
Table 2.3 Organisation types of individuals who participated in Microarray 2012

Chapter 3 DNA Microarray Methods

3.1 This Chapter
3.2 Current Methods
3.3 Future Methods
3.4 Discussion

Figure 3.1 Top ten currently used DNA microarray methods, indicated by individuals who participated in Microarray 2012
Table 3.1 Currently used DNA microarray methods, indicated by individuals who participated in Microarray 2012
Figure 3.2 Other currently used DNA microarray methods, indicated by individuals who participated in Microarray 2012
Table 3.2 Other currently used DNA microarray methods, indicated by individuals who participated in Microarray 2012
Figure 3.3 Top ten DNA microarray methods that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in Microarray 2012
Table 3.3 DNA microarray methods that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in Microarray 2012
Figure 3.4 Other DNA microarray methods that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in Microarray 2012
Table 3.4 Other DNA microarray methods that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in Microarray 2012

Chapter 4 DNA Microarray Applications

4.1 This Chapter
4.2 Current Applications
4.3 Future Applications
4.4 Discussion

Figure 4.1 Top ten currently used DNA microarray applications, indicated by individuals who participated in Microarray 2012
Table 4.1 Currently used DNA microarray applications, indicated by individuals who participated in Microarray 2012
Figure 4.2 Other currently used DNA microarray applications, indicated by individuals who participated in Microarray 2012
Table 4.2 Other currently used DNA microarray applications, indicated by individuals who participated in Microarray 2012
Figure 4.3 Top ten DNA microarray applications that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in Microarray 2012
Table 4.3 DNA microarray applications that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in Microarray 2012
Figure 4.4 Other DNA microarray applications that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in Microarray 2012
Table 4.4 Other DNA microarray applications that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in Microarray 2012

Chapter 5 Companies

5.1 This Chapter
5.2 Current Companies
5.3 Future Companies
5.4 Discussion

Figure 5.1 Top ten DNA microarray company suppliers, currently used by individuals who participated in Microarray 2012
Table 5.1 DNA microarray company suppliers, currently used by individuals who participated in Microarray 2012
Figure 5.2 Other DNA microarray company suppliers, currently used by individuals who participated in Microarray 2012
Table 5.2 Other DNA microarray company suppliers, currently used by individuals who participated in Microarray 2012
Figure 5.3 Top ten DNA microarray company suppliers that end-users anticipated they will be using over the next three years (2012 to 2015), indicated by individuals who participated in Microarray 2012
Table 5.3 DNA microarray company suppliers that end-users anticipated they will be using over the next three years (2012 to 2015), indicated by individuals who participated in Microarray 2012
Figure 5.4 Other DNA microarray company suppliers that end-users anticipated they will be using over the next three years (2012 to 2015), indicated by individuals who participated in Microarray 2012
Table 5.4 Other DNA microarray company suppliers that end-users anticipated they will be using over the next three years (2012 to 2015), indicated by individuals who participated in Microarray 2012

Chapter 6 Preferred Companies and Products

6.1 This Chapter
6.2 Current Methods
6.3 Future Methods
6.4 Strengths
6.5 Weaknesses
6.6 Discussion

Figure 6.1 Top ten preferred suppliers in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Table 6.1 Preferred suppliers in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Figure 6.2 Other preferred suppliers in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Table 6.2 Other preferred suppliers in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Figure 6.3 Top ten preferred products in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Table 6.3 Preferred products in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Figure 6.4 Other preferred products in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Table 6.4 Other Top preferred products in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Figure 6.5 Top ten strengths of preferred products in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Table 6.5 Strengths of preferred products in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Figure 6.6 Other strengths of preferred products in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Table 6.6 Other strengths of preferred products in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Figure 6.7 Top ten weaknesses of preferred products in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Table 6.7 Weaknesses of preferred products in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Figure 6.8 Other weaknesses of preferred products in the DNA microarray field, indicated by individuals who participated in Microarray 2012
Table 6.8 Other weaknesses of preferred products in the DNA microarray field, indicated by individuals who participated in Microarray 2012

Chapter 7 DNA Microarray Expenditure and Budgets

7.1 This Chapter
7.2 Annual Financial Budgets
7.3 Breakdown of Current Financial Budgets
7.4 Breakdown of Future Financial Budgets
7.5 Future Financial Budgets
7.6 Discussion

Figure 7.1 Annual financial budgets for DNA microarray studies, indicated by individuals who participated in Microarray 2012
Table 7.1 Annual financial budgets for DNA microarray studies, indicated by individuals who participated in Microarray 2012
Figure 7.2 The breakdown of current financial budgets for DNA microarray studies, indicated by individuals who participated in Microarray 2012
Table 7.2 The breakdown of current financial budgets for DNA microarray studies, indicated by individuals who participated in Microarray 2012
Figure 7.3 The anticipated future breakdown of financial budgets (over the next three years, 2012 to 2015) for DNA microarray studies, indicated by individuals who participated in Microarray 2012
Table 7.3 The anticipated future breakdown of financial budgets (over the next three years, 2012 to 2015) for DNA microarray studies, indicated by individuals who participated in Microarray 2012

Chapter 8 Purpose of Microarray Use

8.1 This Chapter
8.2 Purpose
8.3 Discussion

Figure 8.1 Top ten reasons for using DNA microarray in the biotechnology industry, indicated by individuals who participated in Microarray 2012
Figure 8.2 Top ten reasons for using DNA microarray in the Chemicals industry, indicated by individuals who participated in Microarray 2012
Figure 8.3 Top ten reasons for using DNA microarray in clinics or hospitals, indicated by individuals who participated in Microarray 2012
Figure 8.4 Top ten reasons for using DNA microarray in the environmental industry, indicated by individuals who participated in Microarray 2012
Figure 8.5 Top ten reasons for using DNA microarray in the food and drink industry, indicated by individuals who participated in Microarray 2012
Figure 8.6 Top ten reasons for using DNA microarray in the forensics industry, indicated by individuals who participated in Microarray 2012
Figure 8.7 Top ten reasons for using DNA microarray in the Government organisations, indicated by individuals who participated in Microarray 2012
Figure 8.8 Top ten reasons for using DNA microarray in the healthcare industry, indicated by individuals who participated in Microarray 2012
Figure 8.9 Top ten reasons for using DNA microarray in the pharmaceutical industry, indicated by individuals who participated in Microarray 2012
Figure 8.10 Top ten reasons for using DNA microarray in research institutes, indicated by individuals who participated in Microarray 2012
Figure 8.11 Top ten reasons for using DNA microarray in universities, indicated by individuals who participated in Microarray 2012

Chapter 9 Samples

9.1 This Chapter
9.2 Samples
9.3 Discussion

Figure 9.1 Top ten sample types analysed using DNA microarray, indicated by individuals who participated in Microarray 2012
Table 9.1 Sample types analysed using DNA microarray, indicated by individuals who participated in Microarray 2012

Chapter 10 Sample Preparation

10.1 This Chapter
10.2 Sample Preparation
10.3 Discussion

Figure 10.1 Top sample preparation methods of DNA microarray users who participated in Microarray 2012
Table 10.1 Sample preparation methods of DNA microarray users who participated in Microarray 2012
Figure 10.2 Other sample preparation methods of DNA microarray users who participated in Microarray 2012
Table 10.2 Other sample preparation methods of DNA microarray users who participated in Microarray 2012

Chapter 11 Therapeutic Areas

11.1 This Chapter
11.2 Therapeutic Areas
11.3 Discussion

Figure 11.1 Top ten therapeutic areas of DNA microarray users who participated in Microarray 2012
Table 11.1 Therapeutic areas of DNA microarray users who participated in Microarray 2012
Figure 11.2 Other therapeutic areas of DNA microarray users who participated in Microarray 2012
Table 11.2 Other therapeutic areas of DNA microarray users who participated in Microarray 2012

Chapter 12 Disease Biomarkers

12.1 This Chapter
12.2 Use of Microarray
12.3 Biomarker Types
12.4 Clinical Utility
12.5 Discussion

Figure 12.1 The use of DNA microarray for the study of disease biomarkers, indicated by individuals who participated in Microarray 2012
Figure 12.2 Principal disease biomarkers studied using DNA microarray, indicated by individuals who participated in Microarray 2012
Table 12.1 Other disease biomarkers studied using DNA microarray, indicated by individuals who participated in Microarray 2012
Figure 12.3 Clinical utilities of disease biomarkers studied using DNA microarray, indicated by individuals who participated in Microarray 2012
Table 12.2 Other clinical utilities of disease biomarkers studied using DNA microarray, indicated by individuals who participated in Microarray 2012

Chapter 13 Bioinformatics Software

13.1 This Chapter
13.2 Bioinformatics Software
13.3 Discussion

Figure 13.1 Top ten bioinformatics software system used for DNA microarray, indicated by users who participated in Microarray 2012
Table 13.1 Bioinformatics software system used for DNA microarray, indicated by users who participated in Microarray 2012
Figure 13.2 Other bioinformatics software system used for DNA microarray, indicated by users who participated in Microarray 2012
Table 13.2 Other bioinformatics software system used for DNA microarray, indicated by users who participated in Microarray 2012

Chapter 14 Challenging Applications

14.1 This Chapter
14.2 Most challenging Molecular Types
14.3 Most challenging Sample Types (Matrices)
14.4 Microarray Methods Used
14.5 Underlying Reasons
14.6 Discussion

Figure 14.1 The most challenging molecular studies using DNA microarray, indicated by users who participated in Microarray 2012
Table 14.1 The most challenging molecular studies using DNA microarray, indicated by users who participated in Microarray 2012
Figure 14.2 The most challenging sample types (matrices) studies using DNA microarray, indicated by users who participated in Microarray 2012
Table 14.2 The most challenging sample types (matrices) studies using DNA microarray, indicated by users who participated in Microarray 2012
Figure 14.3 Top ten DNA microarrays methods used with the most challenging molecular studies using DNA microarray, indicated by users who participated in Microarray 2012
Table 14.3 DNA microarrays methods used with the most challenging molecular studies using DNA microarray, indicated by users who participated in Microarray 2012
Figure 14.4 Top ten underlying reasons for the challenges encountered using DNA microarray analysis, indicated by users who participated in Microarray 2012
Table 14.4 Underlying reasons for the challenges encountered using DNA microarray analysis, indicated by users who participated in Microarray 2012

Chapter 15 Innovation

15.1 This Chapter
15.2 Required Innovation
15.3 Recent Innovation
15.4 Future Innovation
15.5 Discussion

Figure 15.1 Top ten most required areas of innovation in DNA microarray, indicated by individuals who participated in Microarray 2012
Table 15.1 Most required areas of innovation in DNA microarray, indicated by individuals who participated in Microarray 2012
Figure 15.2 Other required areas of innovation in DNA microarray, indicated by individuals who participated in Microarray 2012
Table 15.2 Other required areas of innovation in DNA microarray, indicated by individuals who participated in Microarray 2012
Figure 15.3 Top ten recent innovations (in the last three years) in DNA microarray, indicated by individuals who participated in Microarray 2012
Table 15.3 Recent innovations (in the last three years) in DNA microarray, indicated by individuals who participated in Microarray 2012
Figure 15.4 Top ten future anticipated innovations (in the next three years) in DNA microarray, indicated by individuals who participated in Microarray 2012
Table 15.4 Future anticipated innovations (in the next three years) in DNA microarray, indicated by individuals who participated in Microarray 2012

Chapter 16 Quality Control

16.1 This Chapter
16.2 Quality Control
16.3 Discussion

Figure 16.1 Top ten most commonly used quality control guidelines or procedures used in DNA microarray analysis, indicated by individuals who participated in Microarray 2012
Table 16.1 Quality control guidelines or procedures used in DNA microarray analysis, indicated by individuals who participated in Microarray 2012

Chapter 17 Discussion

To order this report:
Genomics Industry: DNA Microarray 2013: A Focus on Sales Growth

Contact Clare: clare@reportlinker.com  
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker